- Home
- LOCO vs LRMR Comparison
LOCO vs LRMR Comparison
Compare LOCO & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOCO | LRMR |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.2M | 332.1M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | LOCO | LRMR |
|---|---|---|
| Price | $10.71 | $3.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $15.75 | ★ $16.71 |
| AVG Volume (30 Days) | 257.6K | ★ 1.5M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $480,815,000.00 | N/A |
| Revenue This Year | $5.67 | N/A |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | $11.93 | ★ N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $8.29 | $1.61 |
| 52 Week High | $12.65 | $5.37 |
Technical Indicators
Market Signals| Indicator | LOCO | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 55.48 |
| Support Level | $10.46 | $3.34 |
| Resistance Level | $11.74 | $4.05 |
| Average True Range (ATR) | 0.26 | 0.26 |
| MACD | -0.13 | 0.03 |
| Stochastic Oscillator | 21.09 | 77.78 |
Price Performance
Historical ComparisonAbout LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.